Published in Nat Rev Cardiol on March 30, 2010
Marfan syndrome. Part 1: pathophysiology and diagnosis. Nat Rev Cardiol (2010) 1.15
Cardiac remodeling in the mouse model of Marfan syndrome develops into two distinctive phenotypes. Am J Physiol Heart Circ Physiol (2015) 0.78
The role of β-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome. Am J Physiol Heart Circ Physiol (2015) 0.76
Spontaneous pneumothorax as manifestation of Marfan syndrome. BMJ Case Rep (2013) 0.75
Infantile Marfan syndrome in a Korean tertiary referral center. Korean J Pediatr (2016) 0.75
Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet (2003) 11.01
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J (2007) 7.34
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31
Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med (1994) 5.03
Marfan's syndrome. Lancet (2005) 4.99
TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest (2004) 4.85
Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med (1999) 4.17
Life expectancy and causes of death in the Marfan syndrome. N Engl J Med (1972) 3.78
Treatment of aortic disease in patients with Marfan syndrome. Circulation (2005) 3.48
An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg (1992) 3.28
Life expectancy in the Marfan syndrome. Am J Cardiol (1995) 3.14
Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. Ann Thorac Surg (2008) 3.04
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg (2003) 2.23
Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet (2007) 2.16
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J (2005) 2.00
Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation (2004) 1.82
Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol (2005) 1.81
The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. Int J Cardiol (2006) 1.77
Retracted Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA (2007) 1.69
Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. Circulation (1995) 1.69
Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res (2008) 1.67
Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg (1991) 1.66
Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation (2001) 1.63
Distal aortic reinterventions after root surgery in Marfan patients. Ann Thorac Surg (2008) 1.56
Remodeling of the aortic valve anulus. J Thorac Cardiovasc Surg (1993) 1.52
Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation (2009) 1.52
Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg (2008) 1.48
Composite aortic root replacement with a bovine pericardial valve conduit. Ann Thorac Surg (2003) 1.44
Medical management of Marfan syndrome. Circulation (2008) 1.44
A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J (1971) 1.40
A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol (1995) 1.39
Aortic root replacement in 372 Marfan patients: evolution of operative repair over 30 years. Ann Thorac Surg (2009) 1.39
Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.39
Aortic root operations for Marfan syndrome: a comparison of the Bentall and valve-sparing procedures. Ann Thorac Surg (2008) 1.37
Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol (1999) 1.35
Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? J Thorac Cardiovasc Surg (2008) 1.35
Outcome of pregnancy in women with valve prostheses. Br Heart J (1994) 1.27
Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol (1994) 1.24
Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. Circulation (2008) 1.18
Marfan syndrome. Part 1: pathophysiology and diagnosis. Nat Rev Cardiol (2010) 1.15
Maternal and fetal complications of pregnancy in the Marfan syndrome. Am J Med (1981) 1.14
Outcome of pregnancy in women with Marfan's syndrome. Br J Obstet Gynaecol (1997) 1.11
Composite graft repair of Marfan aneurysm of the ascending aorta: results in 100 patients. Ann Thorac Surg (1991) 1.10
Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg (2009) 1.07
Spectrum of aortic operations in 300 patients with confirmed or suspected Marfan syndrome. Ann Thorac Surg (2006) 1.06
Beyond the root: dilatation of the distal aorta in Marfan's syndrome. Heart (2006) 1.06
Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr (2007) 1.05
The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol (1999) 1.05
Mitral valve surgery in the adult Marfan syndrome patient. Ann Thorac Surg (2006) 1.01
Aortic valve-sparing operation in Marfan syndrome: what do we know after a decade? Ann Thorac Surg (2007) 1.01
Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol (2006) 1.00
Aortic valve preservation in patients with aortic root aneurysm: results of the reimplantation technique. Ann Thorac Surg (2007) 1.00
Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: Analysis of early outcome. J Thorac Cardiovasc Surg (2009) 0.97
Long-term results of aortic valve-sparing operations in patients with Marfan syndrome. J Thorac Cardiovasc Surg (2009) 0.97
Obstetric complications in Marfan syndrome. Int J Cardiol (2005) 0.95
Endovascular management of chronic aortic dissection in patients with Marfan syndrome. J Vasc Surg (2009) 0.94
Preimplantation genetic diagnosis of Marfan syndrome using multiple displacement amplification. Fertil Steril (2006) 0.92
Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Am Heart J (1997) 0.90
Stent graft repair of descending aortic dissection in patients with Marfan syndrome: an effective alternative to open reoperation? J Thorac Cardiovasc Surg (2009) 0.88
Maternal complication of pregnancy in Marfan syndrome. Int J Cardiol (2008) 0.88
Cardiovascular surgery in children with Marfan syndrome or Loeys-Dietz syndrome. J Thorac Cardiovasc Surg (2009) 0.87
Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J (1999) 0.85
Mitral valve operation in patients with the Marfan syndrome. J Thorac Cardiovasc Surg (1994) 0.84
Surgical management of mitral regurgitation associated with Marfan's syndrome. Ann Thorac Surg (1998) 0.84
Management of anticoagulants during pregnancy. Heart (2001) 0.84
Pregnancy in women with Marfan's Syndrome. Eur J Obstet Gynecol Reprod Biol (2003) 0.84
Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effects of atenolol. Am J Cardiol (1993) 0.83
External aortic annuloplasty ring for valve-sparing procedures. Ann Thorac Surg (2005) 0.82
Remodeling or reimplantation for valve-sparing aortic root surgery? Ann Thorac Surg (2007) 0.82
Frequency of coronary ostial aneurysms after aortic root surgery in patients with the Marfan syndrome. Am J Cardiol (2002) 0.80
Diseases of the thoracic aorta. Heart (2001) 0.80
Aortic pressure-area relation in Marfan patients with and without beta blocking agents: a new non-invasive approach. Heart (2004) 0.79
Early experience with valve-sparing aortic root replacement in children. Ann Thorac Surg (2005) 0.78
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis (2013) 4.27
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J (2004) 2.85
Training cardiovascular fellows in cardiovascular magnetic resonance and vascular imaging; Current status following the core cardiovascular training symposium (COCATS-2) guidelines. J Am Coll Cardiol (2004) 2.67
Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging (2009) 2.56
Periannular extension of infective endocarditis. J Am Coll Cardiol (2002) 2.53
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging (2012) 2.50
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
[Acute coronary syndrome in infective endocarditis]. Rev Esp Cardiol (2007) 2.35
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging (2013) 2.31
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med (2003) 2.29
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol (2005) 2.23
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation (2004) 2.16
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol (2002) 2.14
Insights into degenerative aortic valve disease. J Am Coll Cardiol (2007) 2.09
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr (2010) 2.06
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 2.00
Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol (2013) 1.93
Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation (2007) 1.91
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87
Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol (2003) 1.86
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol (2002) 1.79
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008) 1.73
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov (2004) 1.71
Targeting preschool children to promote cardiovascular health: cluster randomized trial. Am J Med (2012) 1.70
Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res (2012) 1.68
Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J (2004) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol (2003) 1.67
Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair. J Am Coll Cardiol (2003) 1.67
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation (2004) 1.65
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation (2002) 1.60
Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation (2012) 1.60
New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol (2004) 1.59
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
Myocardial cell therapy at the crossroads. Nat Clin Pract Cardiovasc Med (2007) 1.54